CONSHOHOCKEN, PA--(Marketwire -03/13/12)- NuPathe Inc. (NASDAQ: PATH - News), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, will report fourth quarter and full year 2011 results on Tuesday, March 20, 2012, before the open of the U.S. financial markets. NuPathe will also host a conference call at 8:30 a.m. EDT on the same day to discuss its fourth quarter and full year 2011 financial results and recent operational highlights. A question-and-answer session will follow NuPathe's remarks.
To participate on the live call, please dial 888-797-2982 (domestic) or +1-913-312-0380 (international), and provide the participant passcode 8797224 five to ten minutes before the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 8797224.
A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on NuPathe's website for 90 days following the call.
NuPathe Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. NuPathe is actively seeking partnerships to maximize the commercial potential for our pipeline products in the U.S. and territories throughout the world.
For more information about NuPathe, please visit our website and our blog at www.nupathe.com. You can also follow us on StockTwits (http://stocktwits.com/NuPatheIR), Twitter (https://twitter.com/#!/NuPathe), SlideShare (http://www.slideshare.net/NuPathe), and LinkedIn (http://www.linkedin.com/company/146880).